198 related articles for article (PubMed ID: 20473659)
21. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
22. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
23. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.
Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I
Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.
Gaedigk A; Bhathena A; Ndjountché L; Pearce RE; Abdel-Rahman SM; Alander SW; Bradford LD; Rogan PK; Leeder JS
Pharmacogenomics J; 2005; 5(3):173-82. PubMed ID: 15768052
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.
Masimirembwa CM; Johansson I; Hasler JA; Ingelman-Sundberg M
Pharmacogenetics; 1993 Dec; 3(6):275-80. PubMed ID: 7908586
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I
J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
[TBL] [Abstract][Full Text] [Related]
28. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.
Panserat S; Sica L; Gérard N; Mathieu H; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1999 Jan; 47(1):121-4. PubMed ID: 10073750
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.
Gaedigk A; Eklund JD; Pearce RE; Leeder JS; Alander SW; Phillips MS; Bradford LD; Kennedy MJ
Clin Pharmacol Ther; 2007 Jun; 81(6):817-20. PubMed ID: 17392730
[TBL] [Abstract][Full Text] [Related]
30. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements.
Gaedigk A; Coetsee C
Eur J Clin Pharmacol; 2008 May; 64(5):465-75. PubMed ID: 18202841
[TBL] [Abstract][Full Text] [Related]
31. Allelic and phenotypic characterization of CYP2D6 and its encoded P450 cytochrome enzyme in a serie of Spanish type 1 Gaucher disease patients.
López de Frutos L; Alfonso P; Lahoz C; Irún P; Giraldo P
Med Clin (Barc); 2020 Dec; 155(12):529-534. PubMed ID: 32466973
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
McElroy S; Sachse C; Brockmoller J; Richmond J; Lira M; Friedman D; Roots I; Silber BM; Milos PM
AAPS PharmSci; 2000; 2(4):E33. PubMed ID: 11741249
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6-related oxidation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Foster BC; Casley WL; Rode A; Vloshinsky P; Huang HS; Geertsen S
Can J Physiol Pharmacol; 1997 Mar; 75(3):165-72. PubMed ID: 9164697
[TBL] [Abstract][Full Text] [Related]
34. Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novel CYP2D6*1 haplotypes.
Gaedigk A; Garcia-Ribera C; Jeong HE; Shin JG; Hernandez-Sanchez J
Pharmacogenomics; 2014 Jun; 15(9):1175-84. PubMed ID: 25141893
[TBL] [Abstract][Full Text] [Related]
35. CYP2D6 polymorphism in a Mexican American population.
Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
[TBL] [Abstract][Full Text] [Related]
36. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.
McLellan RA; Oscarson M; Seidegård J; Evans DA; Ingelman-Sundberg M
Pharmacogenetics; 1997 Jun; 7(3):187-91. PubMed ID: 9241658
[TBL] [Abstract][Full Text] [Related]
37. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
38. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 genetic polymorphism in South Indian populations.
Naveen AT; Adithan C; Soya SS; Gerard N; Krishnamoorthy R
Biol Pharm Bull; 2006 Aug; 29(8):1655-8. PubMed ID: 16880622
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
